ArticleEuropean journal of cancer (Oxford, England : 1990)2020
Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion.
Article in European journal of cancer (Oxford, England : 1990), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 72 citations in OpenAlex.
- Cirrhosis, portal hypertension and hepatocellular carcinoma: a stage-based approach.Nature reviews. Gastroenterology & hepatology · 2026Review
- α/β for Hepatocellular Carcinoma Tumors Treated With Radiation Therapy.International journal of radiation oncology, biology, physics · 2026Article
- Irreversible electroporation vs. stereotactic body radiotherapy for solitary hepatocellular carcinoma ≤5 cm: A multicenter retrospective study.JHEP reports : innovation in hepatology · 2026Article
- Outcomes of radiotherapy of hepatocellular carcinoma: a retrospective analysis.Radiation oncology (London, England) · 2026Article
- Utility-Based Dose Selection for Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma.International journal of radiation oncology, biology, physics · 2026Article
- The Contribution of Cirrhosis Progression in Liver Dysfunction After Stereotactic Body Radiation Therapy.International journal of radiation oncology, biology, physics · 2026Article
- The efficacy of sequential radiotherapy after the combination of TACE with lenvatinib and anti-PD-1 antibodies for unresectable HCC.The oncologist · 2026Article
- Functional Avoidance Liver 4π Stereotactic Body Radiation Therapy Informed by Quantitative Gadoxetic Acid Contrast-Enhanced Magnetic Resonance T1 Mapping.International journal of radiation oncology, biology, physics · 2026Article
- Establishment and comparative analysis of radiation-induced liver disease in normal and fibrotic rat models.Precision radiation oncology · 2026Article
- Unexpected Therapeutic Implications: The Abscopal Effect in the Management of Hepatocellular Carcinoma.Cancers · 2026Review
- T1rho MRI as a quantitative biomarker of radiation-induced liver disease in normal and fibrotic rat models.Quantitative imaging in medicine and surgery · 2026Article
- Regulation of glycosylation in radiotherapy: exploring the multiple effects of DNA damage, immune response, stromal microenvironment and metabolism.Frontiers in oncology · 2026Review
- Lenvatinib in combination with radiotherapy versus lenvatinib with transarterial chemoembolization for advanced hepatocellular carcinoma.BMC cancer · 2025Article
- Modern approach to hepatocellular carcinoma treatment.World journal of hepatology · 2025Review
- Assessing the Relationship Between MR-Based Functional Dose Metrics and Post-Stereotactic Body Radiation Therapy Albumin-Bilirubin Change.International journal of radiation oncology, biology, physics · 2025Article
- Sorafenib with or without co-interventions for hepatocellular carcinoma.The Cochrane database of systematic reviews · 2025Review
- Long-Term Survival and Prognostic Factors of Stereotactic Body Radiotherapy Following Transarterial Chemoembolization for Hepatocellular Carcinoma.Cancer reports (Hoboken, N.J.) · 2025Article
- Multi-contrast 4DMR via MR multitasking: Early clinical experience and implication for liver stereotactic body radiation therapy.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2025Article
- Stereotactic body radiation therapy in primary liver tumor: Local control, outcomes and toxicities.Clinical and translational radiation oncology · 2025Article
- Long-term outcomes of more than a decade treating patients with stereotactic body radiation therapy for hepatocellular carcinoma.Clinical and translational radiation oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundStereotactic Body Radiation Therapy (SBRT) is a non-invasive ablative treatment for hepatocellular carcinoma (HCC). This report aimed to address the limited availability of long-term outcomes after SBRT for HCC from North America.
methodsLocalized HCC patients without vascular invasion, who were ineligible for other liver-directed therapies and treated with SBRT at the University of Toronto or University of Michigan, were pooled to determine overall survival (OS), cumulative recurrence rates, and ≥ grade-3 toxicity. Multivariable analysis determined factors affecting OS and local recurrence rates.
resultsIn 297 patients with 436 HCCs (42% > 3 cm), one-, three- and five-year OS was 77·3%, 39·0% and 24·1%, respectively. On Cox proportional hazards regression analysis, liver transplant after SBRT, Child-Pugh A liver function, alpha-fetoprotein ≤ 10 ng/ml, and Eastern Co-operative Oncology Group performance status 0 significantly improved OS (hazard ratio [HR] = 0·06, 95% confidence interval [CI- 0·02-0·25; p<0·001; HR = 0·42, 95% CI = 0·29-0·60, p<0·001; HR = 0·61, 95% CI- 0·44-0·83; p=0·002 and HR = 0·71, 95% CI = 0·51-0·97, p=0·034, respectively). Cumulative local recurrence was 6·3% (95% CI = 0.03-0.09) and 13·3% (95% CI = 0.06-0.21) at one and three years, respectively. Using Cox regression modelling, local control was significantly higher using breath-hold motion management and in HCC smaller than 3 cm (HR = 0.52, 95% CI = 0.58-0.98; p=0.042 and HR = 0.53, 95% CI = 0.26-0.98; p=0.042, respectively). Worsening of Child-Pugh score by ≥2 points three months after SBRT was seen in 15.9%.
conclusionsSBRT confers high local control and long-term survival in a substantial proportion of HCC patients unsuitable for, or refractory to standard loco-regional treatments. Liver transplant should be considered if appropriate downsizing occurs after SBRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.